Previous Close | 4.6000 |
Open | 4.6000 |
Bid | 12.7000 |
Ask | 17.0000 |
Strike | 60.00 |
Expire Date | 2024-05-17 |
Day's Range | 4.6000 - 4.6000 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
Consistent with Analyst Projections Amidst Strategic Advancements
-- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program -- -- VAX-24 Infant Phase 2 Study Enrollment Completed; Topline Data from Primary Immunization Series Expected by End of First Quarter of 2025, Followed by Topline Data from Booster Dose by End of 2025 -- -- $1.9 Billion in Cash, Cash Equivalen
On May 1, 2024, Jim Wassil, the Chief Operating Officer of Vaxcyte Inc (NASDAQ:PCVX), sold 3,000 shares of the company.